6. Diagnostisering

Abouassaly, R., Alibhai, S. M., Shah, N., Timilshina, N., Fleshner, N., & Finelli, A. (2010). Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology, 76(4), 895-901.

Aboumohamed, A. A., Krane, L. S., & Hemal, A. K. (2015). Oncologic Outcomes Following Robot-Assisted Laparoscopic Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma. The Journal of urology, 194(6), 1561-6.

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005). Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. European urology, 48(2), 202-205.

Aksnessæther, B. Y., Lund, J., Myklebust, T., Klepp, O. H., Skovlund, E., Roth Hoff, S., & Solberg, A. (2019). Second cancers in radically treated Norwegian prostate cancer patients. Acta oncologica, 58(6), 838-844.

Alanee, S., Alvarado-Cabrero, I., Murugan, P., Kumar, R., Nepple, K. G., Paner, G. P., Patel, M. I., Raspollini, M. R., ... Konety, B. R. (2019). Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World journal of urology, 37(1), 107-114.

Aleksic, I., Rais-Bahrami, S., Daugherty, M., Agarwal, P. K., Vourganti, S., & Bratslavsky, G. (2018). Primary urethral carcinoma: A Surveillance, Epidemiology, and End Results data analysis identifying predictors of cancer-specific survival. Urology annals, 10(2), 170-174.

Almås, B., Halvorsen, O. J., Johannesen, T. B., & Beisland, C. (2021). Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study. World journal of urology, 39(9), 3385-3391.

Amin, M., Edge, S., Greene, F., Byrd, D. R., Brookland, R. K., Washington, M. K., Gershenwald, J. E. (2017). Renal pelvis and ureter. I: AJCC cancer staging manual. American Joint Committee on Cancer, Springer.

Amin, M., Edge, S., Greene, F., Byrd, D. R., Brookland, R. K., Washington, M. K., Gershenwald, J. E. (2017). AJCC cancer staging manual. American Joint Committee on Cancer, Springer.

Andersson, G., Wennersten, C., Gaber, A., Boman, K., Nodin, B., Uhlen, M., Segersten, U., Malmstrom, P. U., & Jirstrom, K. (2014). Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts. BMC urology, 14, 36.

Andreassen, B. K., Aagnes, B., Gislefoss, R., Andreassen, M., & Wahlqvist, R. (2016). Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014. BMC cancer, 16(1), 799.

Apolo, A. B., Ballman, K. V., Sonpavde, G., Berg, S., Kim, W. Y., Parikh, R., Teo, M. Y., Sweis, R. F., ... Rosenberg, J. E. (2025). Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. New England journal of medicine, 392(1), 45-55.

Arends, T. J., Nativ, O., Maffezzini, M., de Cobelli, O., Canepa, G., Verweij, F., Moskovitz, B., van der Heijden, A. G., & Witjes, J. A. (2016). Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. European urology, 69(6), 1046-52.

Arrizabalaga, M., Extramiana, J., Parra, J. L., Ramos, C., Diaz Gonzalez, R., & Leiva, O. (1987). Treatment of massive haematuria with aluminous salts. BJU international, 60(3), 223-6.

Aziz, N. M. (2007). Cancer survivorship research: state of knowledge, challenges and opportunities. Acta oncologica (Stockholm, Sweden), 46(4), 417-32.

Baard, J., Cormio, L., Cavadas, V., Alcaraz, A., Shariat, S. F., de la Rosette, J., & Laguna, M. P. (2021). Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry. Current opinion in urology, 31(4), 354-362.

Babjuk, M., Burger, M., Compérat, E., Gontero, P., Mostafid, A. H., Palou, J., ... van Rhijn, B. W. G. (2019). Non-muscle-invasive Bladder Cancer (rev. utg.) Arnhem: European Association of Urology. Hentet fra https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/

Babjuk, M., Burger, M., Zigeuner, R., Shariat, S., Van Rhijn, B. W., Compérat, E., Sylvester, R., Kaasinen, E., ... Roupret, M. (2011). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. European urology, 64(4), 639-653.

Baboudjian, M., Al-Balushi, K., Michel, F., Lannes, F., Akiki, A., Gaillet, S., Delaporte, V., Ragni, E., ... Boissier, R. (2020). Diagnostic ureteroscopy prior to nephroureterectomy for urothelial carcinoma is associated with a high risk of bladder recurrence despite technical precautions to avoid tumor spillage. World journal of urology, 38(1), 159-165.

Badawy, A., Sultan, S. M., Marzouk, A., & El-Sherif, E. (2023). Thulium laser en bloc resection versus conventional transurethral resection of urinary bladder tumor: A comparative prospective study. Urology annals, 15(1), 88-94.

Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., ... Galsky, M. D. (2021). Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. New England journal of medicine, 384(22), 2102-2114.

Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., ... Bellmunt, J. (2017). First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. The Lancet. Oncology, 18(11), 1483-1492.

Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., ... Bajorin, D. F. (2017). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, 389(10064), 67-76.

Bamias, A., Davis, I. D., Galsky, M. D., Arranz, J., Kikuchi, E., Grande, E., Del Muro, X. G., Park, S. H., ... De Santis, M. (2024). Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. The Lancet. Oncology, 25(1), 46-61.

Barkan, G. A., Wojcik, E. M., Nayar, R., Savic-Prince, S., Quek, M. L., Kurtycz, D. F. I., & Rosenthal, D. L. (2016). The Paris System for Reporting Urinary Cytology: the quest to develop a standardized terminology. Journal of the American Society of Cytopathology, 5(3), 177-188.

Barrow, P. J., Ingham, S., O'Hara, C., Green, K., McIntyre, I., Lalloo, F., Hill, J., & Evans, D. G. (2013). The spectrum of urological malignancy in Lynch syndrome. Familial cancer, 12(1), 57-63.

Bartkowiak, D., Humble, N., Suhr, P., Hagg, J., Mair, K., Polivka, B., Schneider, U., Bottke, D., & Wiegel, T. (2012). Second cancer after radiotherapy, 1981-2007. Radiotherapy and oncology, 105(1), 122-6.

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., ... Bajorin, D. F. (2017). Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England journal of medicine, 376(11), 1015-1026.

Bellmunt, J., Fougeray, R., Rosenberg, J. E., von der Maase, H., Schutz, F. A., Salhi, Y., Culine, S., & Choueiri, T. K. (2013). Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Annals of oncology, 24(6), 1466-72.

Bellmunt, J., Hussain, M., Gschwend, J. E., Albers, P., Oudard, S., Castellano, D., Daneshmand, S., Nishiyama, H., ... Powles, T. (2021). Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 22(4), 525-537.

Bellmunt, J., Theodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., ... von der Maase, H. (2009). Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. Journal of Clinical Oncology, 27(27), 4454-61.

Berg, S., D'Andrea, D., Vetterlein, M. W., Cole, A. P., Fletcher, S. A., Krimphove, M. J., Marchese, M., Lipsitz, S. R., ... Mossanen, M. (2019). Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. Cancer, 125(9), 1449-1458.

Bernstein, I. T., & Myrhøj, T. (2013). Surveillance for urinary tract cancer in Lynch syndrome. Familial cancer, 12(2), 279-84.

Bhattacharya, A., Li, Y., Shi, Y., & Zhang, Y. (2013). Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination. Carcinogenesis, 34(11), 2593-9.

Birtle, A., Johnson, M., Chester, J., Jones, R., Dolling, D., Bryan, R. T., Harris, C., Winterbottom, A., ... Hall, E. (2020). Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, 395(10232), 1268-1277.

Birtle, A. J., Jones, R., Chester, J., Lewis, R., Biscombe, K., Johnson, M., Blacker, A., Bryan, R. T., ... Hall, E. (2024). Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. Journal of Clinical Oncology, 42(13), 1466-1471.

Blick, C. G., Nazir, S. A., Mallett, S., Turney, B. W., Onwu, N. N., Roberts, I. S., Crew, J. P., & Cowan, N. C. (2012). Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU international, 110(1), 84-94.

Bohle, A., Balck, F., von Weitersheim, J., & Jocham, D. (1996). The quality of life during intravesical bacillus Calmette-Guerin therapy. The Journal of urology, 155(4), 1221-6.

Bohle, A., & Bock, P. R. (2004). Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology, 63(4), 682-686.

Bohle, A., Jocham, D., & Bock, P. R. (2003). Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. The Journal of urology, 169(1), 90-5.

Borhan, A., Reeder, J. E., O'Connell, M. J., Wright, K. O., Wheeless, L. L., di Sant'Agnese, P. A., McNally, M. L., & Messing, E. M. (2003). Grade progression and regression in recurrent urothelial cancer. The Journal of urology, 169(6), 2106-9.

Bouffioux, C., Kurth, K. H., Bono, A., Oosterlinck, W., Kruger, C. B., De Pauw, M., & Sylvester, R. (1995). Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. The Journal of urology, 153(3 Pt 2), 934-41.

Brauers, A., Buettner, R., & Jakse, G. (2001). Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?. The Journal of urology, 165(3), 808-10.

Brausi, M., Collette, L., Kurth, K., van der Meijden, A. P., Oosterlinck, W., Witjes, J. A., Newling, D., Bouffioux, C., ... C, E. G. T. C. (2002). Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies. European urology, 41(5), 523-530.

Bricker, G. V., Riedl, K. M., Ralston, R. A., Tober, K. L., Oberyszyn, T. M., & Schwartz, S. J. (2014). Isothiocyanate metabolism, distribution, and interconversion in mice following consumption of thermally processed broccoli sprouts or purified sulforaphane. Molecular nutrition & food research, 58(10), 1991-2000.

Brien, J. C., Shariat, S. F., Herman, M. P., Ng, C. K., Scherr, D. S., Scoll, B., Uzzo, R. G., Wille, M., ... Raman, J. D. (2010). Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. The Journal of urology, 184(1), 69-73.

Brierley, J. D., Gospodarowicz, M., Wittekind, C. (2017). TNM Classification of Malignant Tumours. Wiley-Blackwell.

Brown, T., Slack, R., & Rushton, L. (2012). Occupational cancer in Britain. Urinary tract cancers: bladder and kidney. British journal of cancer, 107(Suppl 1), S76-84.

Bruins, H. M., Veskimae, E., Hernandez, V., Imamura, M., Neuberger, M. M., Dahm, P., Stewart, F., Lam, T. B., ... Witjes, J. A. (2014). The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. European urology, 66(6), 1065-77.

Bruins, H. M., Visser, O., Ploeg, M., Hulsbergen-van de Kaa, C. A., Kiemeney, L. A., & Witjes, J. A. (2012). The clinical epidemiology of urachal carcinoma: results of a large, population based study. The Journal of urology, 188(4), 1102-7.

Bryan, R. T., Liu, W., Pirrie, S. J., Amir, R., Gallagher, J., Hughes, A. I., Jefferson, K. P., Knight, A., ... James, N. D. (2021). Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. European urology, 80(1), 12-15.

Burger, M., Mulders, P., & Witjes, W. (2012). Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. European urology, 61(5), 1070-1.

Busch, C., & Algaba, F. (2002). The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Archiv : an international journal of pathology, 441(2), 105-8.

Cambier, S., Sylvester, R. J., Collette, L., Gontero, P., Brausi, M. A., van Andel, G., Kirkels, W. J., Silva, F. C., ... Oddens, J. (2016). EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. European urology, 69(1), 60-9.

Capitanio, U., Shariat, S. F., Isbarn, H., Weizer, A., Remzi, M., Roscigno, M., Kikuchi, E., Raman, J. D., ... Karakiewicz, P. I. (2009). Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. European urology, 56(1), 1-9.

Catsburg, C. E., Gago-Dominguez, M., Yuan, J. M., Castelao, J. E., Cortessis, V. K., Pike, M. C., & Stern, M. C. (2014). Dietary sources of N-nitroso compounds and bladder cancer risk: findings from the Los Angeles bladder cancer study. International journal of cancer. Journal international du cancer, 134(1), 125-35.

Chai, Y., Cui, Y., Zhang, X., Zong, H., Zhou, Z., & Zhang, Y. (2021). The efficacy and safety of thulium laser resection of bladder tumor versus standard transurethral resection in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Journal of Men's Health, 17(2), 32-42.

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., ... Stover, D. R. (2016). Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer research, 76(10), 3003-13.

Chang, S. S., Hassan, J. M., Cookson, M. S., Wells, N., & Smith, J. A. ,. J. (2003). Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. The Journal of urology, 170(4 Pt 1), 1085-7.

Chen, Z., Ding, W., Xu, K., Tan, J., Sun, C., Gou, Y., Tong, S., Xia, G., ... Ding, Q. (2012). The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancer. PLoS one, 7(10), e47199.

Cheng, L. (2008). Renal pelvis and ureter. I: D. G. Bostwick & L. Cheng (red.), Urologic surgical pathology (2 utg.) St. Louis, Mo: Mosby Elsevier.

Chitale, S., Mbakada, R., Irving, S., & Burgess, N. (2008). Nephroureterectomy for transitional cell carcinoma - the value of pre-operative histology. Annals of the Royal College of Surgeons of England, 90(1), 45-50.

Choe, J., Braschi-Amirfarzan, M., Tirumani, S. H., Shinagare, A. B., Kim, K. W., Ramaiya, N. H., & Krajewski, K. M. (2017). Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. Abdominal radiology (New York), 42(11), 2710-2724.

Choi, W., Ochoa, A., McConkey, D. J., Aine, M., Höglund, M., Kim, W. Y., Real, F. X., Kiltie, A. E., ... Lerner, S. P. (2017). Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. European urology, 72(3), 354-365.

Choudhury, A., Porta, N., Hall, E., Song, Y. P., Owen, R., MacKay, R., West, C. M. L., Lewis, R., ... Hoskin, P. (2021). Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. The Lancet. Oncology, 22(2), 246-255.

Choueiri, T. K., Jacobus, S., Bellmunt, J., Qu, A., Appleman, L. J., Tretter, C., Bubley, G. J., Stack, E. C., ... Rosenberg, J. E. (2014). Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology, 32(18), 1889-94.

Clements, M. B., Krupski, T. L., & Culp, S. H. (2018). Robotic-Assisted Surgery for Upper Tract Urothelial Carcinoma: A Comparative Survival Analysis. Annals of surgical oncology, 25(9), 2550-2562.

Colin, P., Ouzzane, A., Pignot, G., Ravier, E., Crouzet, S., Ariane, M. M., Audouin, M., Neuzillet, Y., ... Roupret, M. (2012). Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU international, 110(8), 1134-41.

Colt, J., Friesen, M., Stewart, P., Donguk, P., Johnson, A., Schwenn, M., Karagas, M., Armenti, K., ... Silverman, D. (2014). 0084 A Case-Control Study of Occupational Exposure to Metalworking Fluids and Bladder Cancer Risk among Men. Occupational and environmental medicine, 71(Suppl 1), A71.

Cookson, M. S., Chang, S. S., Wells, N., Parekh, D. J., & Smith, J. A. ,. J. (2003). Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. The Journal of urology, 169(1), 101-4.

Cosentino, M., Palou, J., Gaya, J. M., Breda, A., Rodriguez-Faba, O., & Villavicencio-Mavrich, H. (2013). Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World journal of urology, 31(1), 141-5.

Cowan, N. C., Turney, B. W., Taylor, N. J., McCarthy, C. L., & Crew, J. P. (2007). Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU international, 99(6), 1363-70.

Crivelli, J. J., Xylinas, E., Kluth, L. A., Rieken, M., Rink, M., & Shariat, S. F. (2014). Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. European urology, 65(4), 742-54.

Cumberbatch, M. G. K., Foerster, B., Catto, J. W. F., Kamat, A. M., Kassouf, W., Jubber, I., Shariat, S. F., Sylvester, R. J., & Gontero, P. (2018). Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. European urology, 73(6), 925-933.

Cutress, M. L., Stewart, G. D., Wells-Cole, S., Phipps, S., Thomas, B. G., & Tolley, D. A. (2012). Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU international, 110(11), 1608-17.

D'Andrea, D., Soria, F., Hurle, R., Enikeev, D., Kotov, S., Régnier, S., Xylinas, E., Lusuardi, L., ... Shariat, S. F. (2023). En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. European urology oncology, 6(5), 508-515.

Dahl, O., Lehne, G., Baksaas, I., Kvaløy, S., Christoffersen, T. (2009). Medikamentell kreftbehandling, Cytostatikaboken. Farmakologisk institutt, Det medisinske fakultet, Universitetet i Oslo.

Dansk BlæreCancer Gruppe (2023). Behandling og opfølgning af muskelinvasiv blærekræft (2 utg.) Aarhus: DMCG-sekretariatet & Sekretariatet for Kliniske Retningslinjer på Kræftområdet.

Davidsson, T., Hedlund, H., & Månsson, W. (1996). Detubularized right colonic reservoir with intussuscepted ileal nipple valve or stapled ileal ("Lundiana") outlet. Clinical and urodynamic results in a prospective randomized study. World journal of urology, 14(2), 78-84.

de Reijke, T. M., Kurth, K. H., Sylvester, R. J., Hall, R. R., Brausi, M., van de Beek, K., Landsoght, K. E., Carpentier, P., ... Treatment of Cancer-Genito-Urinary, G. (2005). Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). The Journal of urology, 173(2), 405-9.

De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., ... Sylvester, R. (2012). Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. Journal of Clinical Oncology, 30(2), 191-199.

Del Gaizo, A., Silva, A. C., Lam-Himlin, D. M., Allen, B. C., Leyendecker, J., & Kawashima, A. (2013). Magnetic resonance imaging of solid urethral and peri-urethral lesions. Insights Imaging, 4(4), 461-9.

Del Giudice, F., Barchetti, G., De Berardinis, E., Pecoraro, M., Salvo, V., Simone, G., Sciarra, A., Leonardo, C., ... Panebianco, V. (2020). Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. European urology, 77(1), 101-109.

Den norske patologforening (2016). Veileder i biopsibesvarelse av maligne svulster (3 utg.) Oslo: Den norske patologforening. Hentet fra http://legeforeningen.no/Global/Fagmedisinske%20foreninger/Den%20norske%20patologforening/Veileder%20i%20besvarelse%20av%20maligne%20svulster%202016%203%20%20utgave.pdf

Dickman, K. G., Fritsche, H. M., Grollman, A. P., Thalmann, G. N., Catto, J. (2015). Epidemiology and Risk Factors for Upper Urinary Urothelial Cancers. I: E. Xylinas & S. Shariat (red.), Upper Tract Urothelial Carcinoma New York: Springer.

Dimarco, D. S., Dimarco, C. S., Zincke, H., Webb, M. J., Bass, S. E., Slezak, J. M., & Lightner, D. J. (2004). Surgical treatment for local control of female urethral carcinoma. Urologic oncology, 22(5), 404-9.

Dinney, C. P., McConkey, D. J., Millikan, R. E., Wu, X., Bar-Eli, M., Adam, L., Kamat, A. M., Siefker-Radtke, A. O., ... Czerniak, B. (2004). Focus on bladder cancer. Cancer cell, 6(2), 111-6.

Dominguez-Escrig, J. L., Peyronnet, B., Seisen, T., Bruins, H. M., Yuan, C. Y., Babjuk, M., Böhle, A., Burger, M., ... Rouprêt, M. (2019). Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. European urology focus, 5(2), 224-241.

Donat, S. M., Shabsigh, A., Savage, C., Cronin, A. M., Bochner, B. H., Dalbagni, G., Herr, H. W., & Milowsky, M. I. (2009). Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. European urology, 55(1), 177-85.

Draga, R. O., Grimbergen, M. C., Kok, E. T., Jonges, T. N., van Swol, C. F., & Bosch, J. L. (2010). Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy. European urology, 57(4), 655-60.

Drejer, D., Béji, S., Munk Nielsen, A., Høyer, S., Wrist Lam, G., & Jensen, J. B. (2017). Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study. Scandinavian journal of urology, 51(2), 120-123.

Duan, F., Zhai, W., Zhang, B., & Guo, S. (2020). Urachal carcinoma: Impact of recurrence pattern and lymphadenectomy on long-term outcomes. Cancer medicine, 9(12), 4166-4174.

Duchesne, G. M., Bolger, J. J., Griffiths, G. O., Trevor Roberts, J., Graham, J. D., Hoskin, P. J., Fossa, S. D., Uscinska, B. M., & Parmar, M. K. (2000). A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. International journal of radiation oncology, biology, physics, 47(2), 379-88.

EAU (2022). EAU Guidelines. Edition presented at the EAU Annual Congress Amsterdam Arnhem: European Association of Urology.

Eble, J. N., Sauter, G., Epstein, J. I., Sesterhenn, I. (2004). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press.

Efstathiou, J. A., Bae, K., Shipley, W. U., Kaufman, D. S., Hagan, M. P., Heney, N. M., & Sandler, H. M. (2009). Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06. Journal of Clinical Oncology, 27(25), 4055-4061.

Efstathiou, J. A., Spiegel, D. Y., Shipley, W. U., Heney, N. M., Kaufman, D. S., Niemierko, A., Coen, J. J., Skowronski, R. Y., ... Zietman, A. L. (2012). Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. European urology, 61(4), 705-11.

El-Bolkainy, M. N., Chu, E. W., Ghoneim, M. A., & Ibrahim, A. S. (1982). Cytologic detection of bladder cancer in a rural Egyptian population infected with schistosomiasis. Acta cytologica, 26(3), 303-10.

Elmussareh, M., Young, M., Ordell Sundelin, M., Bak-Ipsen, C. B., Graumann, O., & Jensen, J. B. (2017). Outcomes of haematuria referrals: two-year data from a single large university hospital in Denmark. Scandinavian journal of urology, 51(4), 282-289.

Engel, C., Loeffler, M., Steinke, V., Rahner, N., Holinski-Feder, E., Dietmaier, W., Schackert, H. K., Goergens, H., ... Vasen, H. F. (2012). Risks of less common cancers in proven mutation carriers with lynch syndrome. Journal of Clinical Oncology, 30(35), 4409-15.

Epstein, J. I., Amin, M. B., Reuter, V. R., & Mostofi, F. K. (1998). The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. The American journal of surgical pathology, 22(12), 1435-48.

Ericson, K. M., Isinger, A. P., Isfoss, B. L., & Nilbert, M. C. (2005). Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma. BMC cancer, 5, 23.

Eriksson, P., Aine, M., Veerla, S., Liedberg, F., Sjödahl, G., & Höglund, M. (2015). Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. BMC medical genomics, 8, 25.

Fahmy, O., Khairul-Asri, M. G., Schubert, T., Renninger, M., Malek, R., Kubler, H., Stenzl, A., & Gakis, G. (2018). A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urologic oncology, 36(2), 43-53.

Fairey, A. S., Kassouf, W., Estey, E., Tanguay, S., Rendon, R., Bell, D., Izawa, J., Chin, J., ... Jacobsen, N. E. (2013). Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. BJU international, 112(6), 791-7.

Fan, J., Wu, K., Zhang, N., Yang, T., Liu, N., Jiang, Y., Bai, X., Wang, X., & He, D. (2021). Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial. International journal of urology, 28(8), 855-860.

Faraj, K. S., Abdul-Muhsin, H. M., Rose, K. M., Navaratnam, A. K., Patton, M. W., Eversman, S., Singh, R., Eversman, W. G., ... Castle, E. P. (2019). Robot Assisted Radical Cystectomy vs Open Radical Cystectomy: Over 10 years of the Mayo Clinic Experience. Urologic oncology, 37(12), 862-869.

Farnham, S. B., & Cookson, M. S. (2004). Surgical complications of urinary diversion. World journal of urology, 22(3), 157-67.

Figueroa, A. J., Stein, J. P., Dickinson, M., Skinner, E. C., Thangathurai, D., Mikhail, M. S., Boyd, S. D., Lieskovsky, G., & Skinner, D. G. (1998). Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer, 83(1), 141-147.

Flammia, R. S., Chierigo, F., Würnschimmel, C., Horlemann, B., Hoeh, B., Sorce, G., Tian, Z., Leonardo, C., ... Karakiewicz, P. I. (2022). Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma. Urologic oncology, 40(4), 165.e9-165.e15.

Fleischmann, A., Thalmann, G. N., Markwalder, R., & Studer, U. E. (2005). Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. Journal of Clinical Oncology, 23(10), 2358-2365.

Foroudi, F., Pham, D., Bressel, M., Wong, J., Rolfo, A., Roxby, P., & Kron, T. (2012). Bladder cancer radiotherapy margins: a comparison of daily alignment using skin, bone or soft tissue. Clinical oncology, 24(10), 673-81.

Fossa, S. D., Ous, S., & Berner, A. (1991). Clinical significance of the "palpable mass" in patients with muscle-infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. British journal of urology, 67(1), 54-60.

Freedman, N. D., Silverman, D. T., Hollenbeck, A. R., Schatzkin, A., & Abnet, C. C. (2011). Association between smoking and risk of bladder cancer among men and women. Jama, 306(7), 737-45.

Freiha, F., Reese, J., & Torti, F. M. (1996). A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. The Journal of urology, 155(2), 495-9; discussion 499-500.

Fujii, Y., Kawakami, S., Koga, F., Nemoto, T., & Kihara, K. (2003). Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU international, 92(6), 559-62.

Fung, C., Fossa, S. D., Milano, M. T., Oldenburg, J., & Travis, L. B. (2013). Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. Journal of Clinical Oncology, 31(30), 3807-14.

Furrer, M. A., Studer, U. E., Gross, T., Burkhard, F. C., Thalmann, G. N., & Nguyen, D. P. (2018). Nerve-sparing radical cystectomy has a beneficial impact on urinary continence after orthotopic bladder substitution, which becomes even more apparent over time. BJU international, 121(6), 935-944.

Gakis, G., Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E., Cowan, N. C., ... van der Heijden, A. G. (2020). Primary Urethral Carcinoma (7 utg.) Arnhem: EAU Guidelines Office. Hentet fra https://uroweb.org/guideline/primary-urethral-carcinoma/

Gallioli, A., Diana, P., Fontana, M., Territo, A., Rodriguez-Faba, Ó., Gaya, J. M., Sanguedolce, F., Huguet, J., ... Breda, A. (2022). En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial. European urology oncology, 5(4), 440-448.

Galsky, M. D., Arija JÁ, A., Bamias, A., Davis, I. D., De Santis, M., Kikuchi, E., Garcia-Del-Muro, X., De Giorgi, U., ... Grande, E. (2020). Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (London, England), 395(10236), 1547-1557.

Galsky, M. D., Witjes, J. A., Gschwend, J. E., Milowsky, M. I., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., ... Bajorin, D. F. (2025). Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. Journal of Clinical Oncology, 43(1), 15-21.

Galtung, K. F., Lauritzen, P. M., Sandbæk, G., Bay, D., Ponzi, E., Baco, E., Cowan, N. C., Naas, A. M., & Rud, E. (2023). Is a Single Nephrographic Phase Computed Tomography Sufficient for Detecting Urothelial Carcinoma in Patients with Visible Haematuria? A Prospective Paired Noninferiority Comparison. European urology open science, 55, 1-10.

Garcia-Closas, M., Malats, N., Silverman, D., Dosemeci, M., Kogevinas, M., Hein, D. W., Tardon, A., Serra, C., ... Rothman, N. (2005). NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, 366(9486), 649-59.

Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Dei Tos, A. P., Kunkler, I., Otter, R., Licitra, L., ... Capocaccia, R. (2011). Rare cancers are not so rare: the rare cancer burden in Europe. European journal of cancer (Oxford, England : 1990), 47(17), 2493-511.

Ghadjar, P., Burkhard, F. C., Gautschi, O., Thalmann, G. N., & Studer, U. E. (2011). Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU international, 107(6), 894-897.

Ghahestani, S. M., & Shakhssalim, N. (2009). Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review. Urology journal, 6(3), 149-56.

Gheiler, E. L., Tefilli, M. V., Tiguert, R., de Oliveira, J. G., Pontes, J. E., & Wood, D. P. ,. J. (1998). Management of primary urethral cancer. Urology, 52(3), 487-93.

Ghoneim, M. A., & Abol-Enein, H. (2004). Lymphadenectomy with cystectomy: is it necessary and what is its extent?. European urology, 46(4), 457-461.

Giercksky, K., Grønbech, J. E., Hammelbo, T., Hirshberg, H., Lundar, T., Mjåland, O., ... Stangeland, L. (2003). Bruk av palliativ kirurgi i behandlingen av kreftpasienter (SMM-rapport Nr. 8/2003). Oslo: Sintef. Hentet fra www.kunnskapssenteret.no/publikasjoner/_attachment/172405?_ts=14855a78a2d

Girard, A., Rouanne, M., Taconet, S., Radulescu, C., Neuzillet, Y., Girma, A., Beaufrere, A., Lebret, T., ... Grellier, J. F. (2019). Integrated analysis of (18)F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer. European radiology, 29(8), 4286-4293.

Glas, A. S., Roos, D., Deutekom, M., Zwinderman, A. H., Bossuyt, P. M., & Kurth, K. H. (2003). Tumor markers in the diagnosis of primary bladder cancer. A systematic review. The Journal of urology, 169(6), 1975-82.

Gofrit, O. N., Pode, D., Lazar, A., Katz, R., & Shapiro, A. (2006). Watchful waiting policy in recurrent Ta G1 bladder tumors. European urology, 49(2), 303-6; discussion 306-7.

Gofrit, O. N., Yutkin, V., Shapiro, A., Pizov, G., Zorn, K. C., Hidas, G., Gielchinsky, I., Duvdevani, M., ... Pode, D. (2016). The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer. Frontiers in oncology, 6, 43.

Gogna, N. K., Matthews, J. H., Turner, S. L., Mameghan, H., Duchesne, G. M., Spry, N., Berry, M. P., Keller, J., ... Trans Tasman Radiation Oncology, G. (2006). Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiotherapy and oncology, 81(1), 9-17.

Gönul, ,. I., Akyürek, N., Dursun, A., & Küpeli, B. (2008). Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathology, research and practice, 204(10), 707-17.

Gonzalez, A. N., Lipsky, M. J., Li, G., Rutman, M. P., Cooper, K. L., Weiner, D. M., Badalato, G., Decastro, G. J., ... Anderson, C. B. (2019). The Prevalence of Bladder Cancer During Cystoscopy for Asymptomatic Microscopic Hematuria. Urology, 126, 34-38.

Gregg, R. W., Vera-Badillo, F. E., Booth, C. M., Mahmud, A., Brundage, M., Leveridge, M. J., & Hanna, T. P. (2018). Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: A systematic review and meta-analysis. Critical reviews in oncology/hematology, 128, 58-64.

Griffiths, T. R., Charlton, M., Neal, D. E., & Powell, P. H. (2002). Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. The Journal of urology, 167(6), 2408-12.

Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., deVere White, R. W., Sarosdy, M. F., ... Crawford, E. D. (2003). Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New England journal of medicine, 349(9), 859-66.

Grotenhuis, A. J., Vermeulen, S. H., & Kiemeney, L. A. (2010). Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response. Future oncology (London, England), 6(9), 1433-60.

Gschwend, J. E., Heck, M. M., Lehmann, J., Rübben, H., Albers, P., Wolff, J. M., Frohneberg, D., de Geeter, P., ... Retz, M. (2019). Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. European urology, 75(4), 604-611.

Gudjónsson, S., Adell, L., Merdasa, F., Olsson, R., Larsson, B., Davidsson, T., Richthoff, J., Hagberg, G., ... Liedberg, F. (2009). Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. European urology, 55(4), 773-80.

Guo, R. Q., Hong, P., Xiong, G. Y., Zhang, L., Fang, D., Li, X. S., Zhang, K., & Zhou, L. Q. (2018). Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis. BJU international, 121(2), 184-193.

Guzzo, T. J., Rogers, C. G., Deng, C. Y., Bivalacqua, T. J., Palapattu, G. S., Bastian, P. J., Eisenberger, M. A., Schoenberg, M. P., & Gonzalgo, M. L. (2008). Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease. BJU international, 102(11), 1539-43.

Hakenberg, O. W., Compérat, E., Minhas, S., Necchi, A., Protzel, C., Watkin, N., Robinson, R. (2017). EAU Guidelines on Penile Cancer Arnhem: European Association of Urology. Hentet fra https://uroweb.org/guidelines/archive/penile-cancer

Han, R. F., & Pan, J. G. (2006). Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology, 67(6), 1216-1223.

Hanna, N., Sun, M., Trinh, Q. D., Hansen, J., Bianchi, M., Montorsi, F., Shariat, S. F., Graefen, M., ... Karakiewicz, P. I. (2012). Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series. European urology, 61(4), 715-21.

Hashem, A., Mosbah, A., El-Tabey, N. A., Laymon, M., Ibrahiem, E. H., Elhamid, M. A., & Elshal, A. M. (2021). Holmium Laser En-bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle-invasive Bladder Cancer: A Randomized Clinical Trial. European urology focus, 7(5), 1035-1043.

Haugnes, H. S., Bosl, G. J., Boer, H., Gietema, J. A., Brydoy, M., Oldenburg, J., Dahl, A. A., Bremnes, R. M., & Fossa, S. D. (2012). Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. Journal of Clinical Oncology, 30(30), 3752-3763.

Hautmann, R. E., de Petriconi, R. C., Pfeiffer, C., & Volkmer, B. G. (2012). Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. European urology, 61(5), 1039-47.

Hautmann, R. E., de Petriconi, R. C., & Volkmer, B. G. (2010). Lessons learned from 1,000 neobladders: the 90-day complication rate. The Journal of urology, 184(3), 990-4; quiz 1235.

Hautmann, R. E., Volkmer, B. G., Schumacher, M. C., Gschwend, J. E., & Studer, U. E. (2006). Long-term results of standard procedures in urology: the ileal neobladder. World journal of urology, 24(3), 305-14.

Helenius, M., Brekkan, E., Dahlman, P., Lönnemark, M., & Magnusson, A. (2015). Bladder cancer detection in patients with gross haematuria: Computed tomography urography with enhancement-triggered scan versus flexible cystoscopy. Scandinavian journal of urology, 49(5), 377-81.

Helenius, M., Dahlman, P., Lonnemark, M., Brekkan, E., Wernroth, L., & Magnusson, A. (2016). Comparison of post contrast CT urography phases in bladder cancer detection. European radiology, 26(2), 585-91.

Helenius, M., Dahlman, P., Magnusson, M., Lönnemark, M., & Magnusson, A. (2014). Contrast enhancement in bladder tumors examined with CT urography using traditional scan phases. Acta radiologica, 55(9), 1129-36.

Heller, M. T., & Tublin, M. E. (2014). In search of a consensus: evaluation of the patient with hematuria in an era of cost containment. AJR. American journal of roentgenology, 202(6), 1179-86.

Helsedirektoratet (2017). Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft i tykktarm og endetarm (IS-2644). Oslo: Helsedirektoratet. Hentet fra https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-kreft-i-tykktarm-og-endetarm

Helsedirektoratet (14. oktober 2019). Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen. [nettdokument]. Oslo: Helsedirektoratet. Hentet 25. september 2024 fra https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-palliasjon-i-kreftomsorgen

Herman, J. M., Smith, D. C., Montie, J., Hayman, J. A., Sullivan, M. A., Kent, E., Griffith, K. A., Esper, P., & Sandler, H. M. (2004). Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology, 64(1), 69-73.

Hermann, G. G., Mogensen, K., Carlsson, S., Marcussen, N., & Duun, S. (2011). Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU international, 108(8 Pt 2), E297-303.

Herr, H. W. (2012). Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria. The Journal of urology, 187(2), 435-7.

Herr, H. W., Bochner, B. H., Dalbagni, G., Donat, S. M., Reuter, V. E., & Bajorin, D. F. (2002). Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. The Journal of urology, 167(3), 1295-8.

Herr, H. W., Cookson, M. S., & Soloway, S. M. (1996). Upper tract tumors in patients with primary bladder cancer followed for 15 years. The Journal of urology, 156(4), 1286-7.

Herr, H. W., & Dalbagni, G. (2003). Defining bacillus Calmette-Guerin refractory superficial bladder tumors. The Journal of urology, 169(5), 1706-8.

Herr, H. W., Donat, S. M., & Bajorin, D. F. (2001). Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. The Journal of urology, 165(3), 811-4.

Herr, H. W., Donat, S. M., & Reuter, V. E. (2007). Management of low grade papillary bladder tumors. The Journal of urology, 178(4 Pt 1), 1201-5; discussion 1205.

Herr, H. W., & Scher, H. I. (1990). Surgery of invasive bladder cancer: is pathologic staging necessary?. Seminars in Oncology, 17(5), 590-597.

Hoffman, A., Yossepowitch, O., Erlich, Y., Holland, R., & Lifshitz, D. (2014). Oncologic results of nephron sparing endoscopic approach for upper tract low grade transitional cell carcinoma in comparison to nephroureterectomy - a case control study. BMC urology, 14, 97.

Holmang, S., Andius, P., Hedelin, H., Wester, K., Busch, C., & Johansson, S. L. (2001). Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. The Journal of urology, 165(4), 1124-8; discussion 1128-30.

Holmang, S., & Johansson, S. L. (2002). Stage Ta-T1 bladder cancer: The relationship between findings at first followup cystoscopy and subsequent recurrence and progression. The Journal of urology, 167(4), 1634-1637.

Huncharek, M., Muscat, J., & Geschwind, J. F. (1998). Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer research, 18(3B), 1931-1934.

Hungerhuber, E., Stepp, H., Kriegmair, M., Stief, C., Hofstetter, A., Hartmann, A., Knuechel, R., Karl, A., ... Zaak, D. (2007). Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology, 69(2), 260-4.

Hurle, R., Lazzeri, M., Colombo, P., Buffi, N., Morenghi, E., Peschechera, R., Castaldo, L., Pasini, L., ... Guazzoni, G. (2016). "En Bloc" Resection of Nonmuscle Invasive Bladder Cancer: A Prospective Single-center Study. Urology, 90, 126-30.

Hurle, R., Losa, A., Manzetti, A., & Lembo, A. (1999). Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. Urology, 53(6), 1144-1148.

Hussain, S. A., Porta, N., Hall, E., Salawu, A., Lewis, R., Sreenivasan, T., Wallace, J., Crundwell, M., ... James, N. D. (2021). Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. European urology, 79(2), 307-315.

IARC (2007). Cancer Incidence in Five Continents (IARC Scientific Publications No. 160). Lyon: IARC.

Inman, B. A., Tran, V. T., Fradet, Y., & Lacombe, L. (2009). Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer, 115(13), 2853-62.

International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research, Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, ... Parmar, M. K. (2011). International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. Journal of Clinical Oncology, 29(16), 2171-7.

Itani, M., Kielar, A., Menias, C. O., Dighe, M. K., Surabhi, V., Prasad, S. R., O'Malley, R., Gangadhar, K., & Lalwani, N. (2016). MRI of female urethra and periurethral pathologies. International urogynecology journal, 27(2), 195-204.

Ito, A., Shintaku, I., Satoh, M., Ioritani, N., Aizawa, M., Tochigi, T., Kawamura, S., Aoki, H., ... Arai, Y. (2013). Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. Journal of Clinical Oncology, 31(11), 1422-7.

Ito, Y., Kikuchi, E., Tanaka, N., Miyajima, A., Mikami, S., Jinzaki, M., & Oya, M. (2011). Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. The Journal of urology, 185(5), 1621-6.

Jahnson, S., Wiklund, F., Duchek, M., Mestad, O., Rintala, E., Hellsten, S., & Malmstrom, P. U. (2005). Results of second-look resection after primary resection of T1 tumour of the urinary bladder. Scandinavian journal of urology and nephrology, 39(3), 206-10.

Jakse, G., Algaba, F., Malmström, P. U., & Oosterlinck, W. (2004). A second-look TUR in T1 transitional cell carcinoma: why?. European urology, 45(5), 539-46; discussion 546.

Jakse, G., Hall, R., Bono, A., Holtl, W., Carpentier, P., Spaander, J. P., van der Meijden, A. P., & Sylvester, R. (2001). Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. European urology, 40(2), 144-150.

James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., Crundwell, M., Sizer, B., ... Huddart, R. A. (2012). Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. New England journal of medicine, 366(16), 1477-88.

Jia, Z., Chang, X., Li, X., Wang, B., & Zhang, X. (2020). Urachal Carcinoma: Are Lymphadenectomy and Umbilectomy Necessary?. Medical science monitor, 26, e927913.

Jichlinski, P., Guillou, L., Karlsen, S. J., Malmström, P. U., Jocham, D., Brennhovd, B., Johansson, E., Gartner, T., ... Leisinger, H. J. (2003). Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. The Journal of urology, 170(1), 226-9.

Ju, J. Y., Mills, A. M., Mahadevan, M. S., Fan, J., Culp, S. H., Thomas, M. H., & Cathro, H. P. (2018). Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas. The American journal of surgical pathology, 42(11), 1549-1555.

Kamat, A. M., Dinney, C. P., Gee, J. R., Grossman, H. B., Siefker-Radtke, A. O., Tamboli, P., Detry, M. A., Robinson, T. L., & Pisters, L. L. (2007). Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer, 110(1), 62-7.

Kamat, A. M., Huang, S. F., Bermejo, C. E., Rosser, C. J., Pettaway, C. A., Pisters, P. W., Guitreau, D., & Pisters, L. L. (2003). Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. The Journal of urology, 170(5), 1868-71.

Karanović, S., Vuković-Lela, I., Miller, F., Edwards, K. L., Nikolić, J., Tomić, K., Slade, N., Brdar, B., ... Dickman, K. G. (2012). Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney international, 81(6), 559-67.

Karnes, R. J., Breau, R. H., & Lightner, D. J. (2010). Surgery for urethral cancer. The Urologic clinics of North America, 37(3), 445-57.

Kava, B. R., Abol-Enein, H., Baniel, J., Carmack, A., Coquhoun, A., Turner, W. (2012). Non-urothelial Cancer of the Urinary Bladder. I: M. S. Soloway & S. Khoury (red.), Bladder cancer (2 utg.) Paris: European Association of Urology og ICUS. Hentet fra http://www.icud.info/PDFs/Bladder%20Cancer%20Second%20Edition%202012.pdf

Khadra, M. H., Pickard, R. S., Charlton, M., Powell, P. H., & Neal, D. E. (2000). A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. The Journal of urology, 163(2), 524-7.

Khan, M. S., Thornhill, J. A., Gaffney, E., Loftus, B., & Butler, M. R. (2002). Keratinising squamous metaplasia of the bladder: natural history and rationalization of management based on review of 54 years experience. European urology, 42(5), 469-74.

Khetrapal, P., Wong, J. K. L., Tan, W. P., Rupasinghe, T., Tan, W. S., Williams, S. B., Boorjian, S. A., Wijburg, C., ... Kelly, J. D. (2023). Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials. European urology, 84(4), 393-405.

Kiemeney, L. A., Sulem, P., Besenbacher, S., Vermeulen, S. H., Sigurdsson, A., Thorleifsson, G., Gudbjartsson, D. F., Stacey, S. N., ... Stefansson, K. (2010). A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nature genetics, 42(5), 415-9.

Kim, J. Y., Kim, S. H., Lee, H. J., Kim, M. J., Kim, Y. H., & Cho, S. H. (2014). MDCT urography for detecting recurrence after transurethral resection of bladder cancer: comparison of nephrographic phase with pyelographic phase. AJR. American journal of roentgenology, 203(5), 1021-7.

Kim, S. P., Frank, I., Cheville, J. C., Thompson, R. H., Weight, C. J., Thapa, P., & Boorjian, S. A. (2012). The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. The Journal of urology, 188(2), 405-9.

Kirkali, Z., Chan, T., Manoharan, M., Algaba, F., Busch, C., Cheng, L., Kiemeney, L., Kriegmair, M., ... Weider, J. (2005). Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology, 66(6 Suppl 1), 4-34.

Kjøbli, E., Salvesen, Ø., Langørgen, S., Størkersen, Ø., Wibe, A., & Arum, C. J. (2023). En bloc radical cystectomy: An overview of the technique and oncological results. BJUI compass, 4(2), 195-205.

Koay, E. J., Teh, B. S., Paulino, A. C., & Butler, E. B. (2011). A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends. Cancer, 117(23), 5325-33.

Kondo, T., Nakazawa, H., Ito, F., Hashimoto, Y., Toma, H., & Tanabe, K. (2007). Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract. Urology, 69(2), 265-9.

Krajewski, W., Koscielska-Kasprzak, K., Rymaszewska, J., & Zdrojowy, R. (2017). How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 26(3), 625-634.

Krajewski, W., Chorbińska, J., Kiełb, P., Sut, M., Moschini, M., Teoh, J. Y., Mori, K., Del Giudice, F., ... Szydełko, T. (2021). The Impact of Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma: A Comprehensive Systematic Review and Meta-Analysis. Journal of clinical medicine, 10(18), 4197.

Kramer, M. W., Altieri, V., Hurle, R., Lusuardi, L., Merseburger, A. S., Rassweiler, J., Struck, J. P., & Herrmann, T. R. W. (2017). Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. European urology focus, 3(6), 567-576.

Kramer, M. W., Rassweiler, J. J., Klein, J., Martov, A., Baykov, N., Lusuardi, L., Janetschek, G., Hurle, R., ... Herrmann, T. R. (2015). En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World journal of urology, 33(12), 1937-43.

Kulkarni, G. S., Hakenberg, O. W., Gschwend, J. E., Thalmann, G., Kassouf, W., Kamat, A., & Zlotta, A. (2010). An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. European urology, 57(1), 60-70.

Kupershmidt, M., Margolis, M., Jang, H. J., Massey, C., & Metser, U. (2011). Evaluation of upper urinary tract tumors with portal venous phase MDCT: a case-control study. AJR. American journal of roentgenology, 197(2), 424-8.

Lagrange, J. L., Bascoul-Mollevi, C., Geoffrois, L., Beckendorf, V., Ferrero, J. M., Joly, F., Allouache, N., Bachaud, J. M., ... Study Group on Genito-Urinary, T. (2011). Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). International journal of radiation oncology, biology, physics, 79(1), 172-8.

Lamm, D. L. (1992). Carcinoma in situ. The Urologic clinics of North America, 19(3), 499-508.

Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A., Sarosdy, M. F., Bohl, R. D., ... Crawford, E. D. (2000). Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. The Journal of urology, 163(4), 1124-9.

Lamm, D. L., & Riggs, D. R. (2001). Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. The Journal of nutrition, 131(3s), 1067s-70s.

Lammers, R. J., Witjes, W. P., Hendricksen, K., Caris, C. T., Janzing-Pastors, M. H., & Witjes, J. A. (2011). Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. European urology, 60(4), 713-20.

Larsen, I. K. (2021). Cancer in Norway 2020: cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Leblanc, B., Duclos, A. J., Benard, F., Cote, J., Valiquette, L., Paquin, J. M., Mauffette, F., Faucher, R., & Perreault, J. P. (1999). Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. The Journal of urology, 162(6), 1946-50.

Lee, Y. J., Moon, K. C., Jeong, C. W., Kwak, C., Kim, H. H., & Ku, J. H. (2014). Impact of squamous and glandular differentiation on oncologic outcomes in upper and lower tract urothelial carcinoma. PLoS one, 9(9), e107027.

Lehmann, J., Franzaring, L., Thuroff, J., Wellek, S., & Stockle, M. (2006). Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU international, 97(1), 42-7.

Leibovici, D., Kamat, A. M., Pettaway, C. A., Pagliaro, L., Rosser, C. J., Logothetis, C., & Pisters, L. L. (2005). Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. The Journal of urology, 174(6), 2186-90.

Leissner, J., Hohenfellner, R., Thuroff, J. W., & Wolf, H. K. (2000). Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU international, 85(7), 817-23.

Leow, J. J., Martin-Doyle, W., Rajagopal, P. S., Patel, C. G., Anderson, E. M., Rothman, A. T., Cote, R. J., Urun, Y., ... Bellmunt, J. (2013). Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. European urology, 66(1), 42-54.

Lerner, S. P., Tangen, C., Svatek, R. S., Daneshmand, S., Pohar, K., Skinner, E., Schuckman, A., Sagalowsky, A. I., ... Thompson, I. M. (2024). Swog S1011-Subgroup Analysis of the Phase Iii Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer. The Journal of urology, 211(5 Suppl 2), e2.

Li, G., Hu, J., & Niu, Y. (2018). Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy. Oncotarget, 9(1), 217-223.

Li, Z., Zhou, Z., Cui, Y., & Zhang, Y. (2022). Systematic review and meta-analysis of randomized controlled trials of perioperative outcomes and prognosis of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer. International journal of surgery, 104, 106777.

Liedberg, F., Chebil, G., & Månsson, W. (2007). Urothelial carcinoma in the prostatic urethra and prostate: current controversies. Expert review of anticancer therapy, 7(3), 383-90.

Liguori, G., Amodeo, A., Mucelli, F. P., Patel, H., Marco, D., Belgrano, E., & Trombetta, C. (2010). Intractable haematuria: long-term results after selective embolization of the internal iliac arteries. BJU international, 106(4), 500-3.

Loizzo, D., Pandolfo, S. D., Crocerossa, F., Guruli, G., Ferro, M., Paul, A. K., Imbimbo, C., Lucarelli, G., ... Autorino, R. (2022). Current Management of Urachal Carcinoma: An Evidence-based Guide for Clinical Practice. European urology open science, 39, 1-6.

Lokeshwar, V. B., Habuchi, T., Grossman, H. B., Murphy, W. M., Hautmann, S. H., Hemstreet, G. P. ,. 3., Bono, A. V., Getzenberg, R. H., ... Droller, M. J. (2005). Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology, 66(6 Suppl 1), 35-63.

Loo, R. K., Lieberman, S. F., Slezak, J. M., Landa, H. M., Mariani, A. J., Nicolaisen, G., Aspera, A. M., & Jacobsen, S. J. (2013). Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clinic proceedings, 88(2), 129-38.

Loriot, Y., Matsubara, N., Park, S. H., Huddart, R. A., Burgess, E. F., Houede, N., Banek, S., Guadalupi, V., ... Siefker-Radtke, A. O. (2023). Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. New England journal of medicine, 389(21), 1961-1971.

Losa, A., Hurle, R., & Lembo, A. (2000). Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. The Journal of urology, 163(1), 68-71.

Lotan, Y., & Roehrborn, C. G. (2003). Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology, 61(1), 109-18; discussion 118.

Lughezzani, G., Jeldres, C., Isbarn, H., Shariat, S. F., Sun, M., Pharand, D., Widmer, H., Arjane, P., ... Karakiewicz, P. I. (2010). A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology, 75(1), 118-24.

Macejko, A. M., Pazona, J. F., Loeb, S., Kimm, S., & Nadler, R. B. (2008). Management of distal ureter in laparoscopic nephroureterectomy--a comprehensive review of techniques. Urology, 72(5), 974-81.

Madersbacher, S., Schmidt, J., Eberle, J. M., Thoeny, H. C., Burkhard, F., Hochreiter, W., & Studer, U. E. (2003). Long-term outcome of ileal conduit diversion. The Journal of urology, 169(3), 985-90.

Majewski, W., & Tarnawski, R. (2009). Acute and late toxicity in radical radiotherapy for bladder cancer. Clinical oncology, 21(8), 598-609.

Malmström, P. U., Skaaheim Haug, E., Boström, P. J., Gudjónsson, S., & Bjerggaard Jensen, J. (2019). Progress towards a Nordic standard for the investigation of hematuria: 2019. Scandinavian journal of urology, 53(1), 1-6.

Mangar, S. A., Foo, K., Norman, A., Khoo, V., Shahidi, M., Dearnaley, D. P., Horwich, A., & Huddart, R. A. (2006). Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer. Clinical oncology, 18(6), 466-73.

Margulis, V., Shariat, S. F., Matin, S. F., Kamat, A. M., Zigeuner, R., Kikuchi, E., Lotan, Y., Weizer, A., ... Wood, C. G. (2009). Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 115(6), 1224-33.

Mariappan, P., & Smith, G. (2005). A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. The Journal of urology, 173(4), 1108-1111.

Martinez-Pineiro, J. A., Flores, N., Isorna, S., Solsona, E., Sebastian, J. L., Pertusa, C., Rioja, L. A., Martinez-Pineiro, L., ... Cueto (2002). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU international, 89(7), 671-680.

Martinez-Pineiro, J. A., Martinez-Pineiro, L., Solsona, E., Rodriguez, R. H., Gomez, J. M., Martin, M. G., Molina, J. R., Collado, A. G., ... Madero, R. (2005). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. The Journal of urology, 174(4 Pt 1), 1242-1247.

Matin, S. F., Sfakianos, J. P., Espiritu, P. N., Coleman, J. A., & Spiess, P. E. (2015). Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. The Journal of urology, 194(6), 1567-74.

Matulay, J. T., Narayan, V. M., & Kamat, A. M. (2019). Clinical and Genomic Considerations for Variant Histology in Bladder Cancer. Current oncology reports, 21(3), 23.

Matzkin, H., Soloway, M. S., & Hardeman, S. (1991). Transitional cell carcinoma of the prostate. The Journal of urology, 146(5), 1207-12.

Maurer, T., Horn, T., Heck, M., Gschwend, J. E., Eiber, M., & Beer, A. J. (2013). Current Staging Procedures in Urinary Bladder Cancer. Diagnostics (Basel, Switzerland), 3(3), 315-24.

Melicow, M. M. (1955). Tumors of the urinary bladder: a clinico-pathological analysis of over 2500 specimens and biopsies. The Journal of urology, 74(4), 498-521.

Metcalfe, M. J., Petros, F. G., Rao, P., Mork, M. E., Xiao, L., Broaddus, R. R., & Matin, S. F. (2018). Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. The Journal of urology, 199(1), 60-65.

Metser, U., Goldstein, M. A., Chawla, T. P., Fleshner, N. E., Jacks, L. M., & O'Malley, M. E. (2012). Detection of urothelial tumors: comparison of urothelial phase with excretory phase CT urography--a prospective study. Radiology, 264(1), 110-8.

Migliari, R., Buffardi, A., & Ghabin, H. (2015). Thulium Laser Endoscopic En Bloc Enucleation of Nonmuscle-Invasive Bladder Cancer. Journal of endourology, 29(11), 1258-62.

Miladi, M., Peyromaure, M., Zerbib, M., Saighi, D., & Debre, B. (2003). The value of a second transurethral resection in evaluating patients with bladder tumours. European urology, 43(3), 241-5.

Millikan, R., Dinney, C., Swanson, D., Sweeney, P., Ro, J. Y., Smith, T. L., Williams, D., & Logothetis, C. (2001). Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. Journal of Clinical Oncology, 19(20), 4005-4013.

Milojevic, B., Djokic, M., Sipetic-Grujicic, S., Grozdic Milojevic, I., Vuksanovic, A., Nikic, P., Vukovic, I., Djordjevic, D., ... Tulic, C. (2013). Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. Urologic oncology, 31(8), 1615-20.

Mirza, A., & Choudhury, A. (2016). Bladder Preservation for Muscle Invasive Bladder Cancer. Bladder cancer (Amsterdam, Netherlands), 2(2), 151-163.

Mohr, D. N., Offord, K. P., & Melton, L. J. ,. 3. (1987). Isolated asymptomatic microhematuria: a cross-sectional analysis of test-positive and test-negative patients. Journal of general internal medicine, 2(5), 318-24.

Moloney, F., Murphy, K. P., Twomey, M., O'Connor, O. J., & Maher, M. M. (2014). Haematuria: an imaging guide. Advances in urology, 2014, 414125.

Mork, M., Hubosky, S. G., Rouprêt, M., Margulis, V., Raman, J., Lotan, Y., O'Brien, T., You, N., ... Matin, S. F. (2015). Lynch Syndrome: A Primer for Urologists and Panel Recommendations. The Journal of urology, 194(1), 21-9.

Moschini, M., D'Andrea, D., Korn, S., Irmak, Y., Soria, F., Compérat, E., & Shariat, S. F. (2017). Characteristics and clinical significance of histological variants of bladder cancer. Nature reviews. Urology, 14(11), 651-668.

Moschini, M., Karnes, R. J., Suardi, N., Bianchi, M., Pellucchi, F., Rocchini, L., Damiano, R., Serretta, V., ... Colombo, R. (2016). Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. Clinical genitourinary cancer, 14(3), e245-50.

Mostofi, F. K., Davis, C. J., Sesterhenn, I. A. (1999). Histological typing of urinary bladder tumours (2 utg.) Berlin og New York: Springer.

Mostofi, F. K., Sobin, L. H., Torloni, H. (1973). Histological typing of urinary bladder tumours (International histological classification of tumours No. 10). Geneva: World Health Orgaization. Hentet fra http://apps.who.int/iris/bitstream/10665/41533/1/9241760109_eng.pdf

Mowatt, G., N'Dow, J., Vale, L., Nabi, G., Boachie, C., Cook, J. A., Fraser, C., & Griffiths, T. R. (2011). Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. International journal of technology assessment in health care, 27(1), 3-10.

Mungan, M. U., Canda, A. E., Tuzel, E., Yorukoglu, K., & Kirkali, Z. (2005). Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. European urology, 48(5), 760-3.

Myers, J. B., & Lenherr, S. M. (2016). Perioperative and long-term surgical complications for the Indiana pouch and similar continent catheterizable urinary diversions. Current opinion in urology, 26(4), 376-82.

Naito, S., Algaba, F., Babjuk, M., Bryan, R. T., Sun, Y. H., Valiquette, L., & de la Rosette, J. (2016). The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results. European urology, 70(3), 506-15.

Neal, D. E. (1985). Complications of ileal conduit diversion in adults with cancer followed up for at least five years. British medical journal, 290(6483), 1695-1697.

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., ... Montorsi, F. (2018). Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 36(34), 3353-3360.

Nelles, J. L., Konety, B. R., Saigal, C., Pace, J., Lai, J., & Urologic Diseases in America Project (2008). Urethrectomy following cystectomy for bladder cancer in men: practice patterns and impact on survival. The Journal of urology, 180(5), 1933-6; discussion 1936-7.

Ni, S., Tao, W., Chen, Q., Liu, L., Jiang, H., Hu, H., Han, R., & Wang, C. (2012). Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. European urology, 61(6), 1142-53.

Nieuwenhuijzen, J. A., Bex, A., Meinhardt, W., Kerst, J. M., Schornagel, J. H., H, V. A. N. T., & Horenblas, S. (2005). Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. The Journal of urology, 174(1), 80-5.

Nieuwenhuijzen, J. A., Horenblas, S., Meinhardt, W., van Tinteren, H., & Moonen, L. M. (2004). Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU international, 94(6), 793-7.

O'Brien, T., Ray, E., Singh, R., Coker, B., & Beard, R. (2011). Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). European urology, 60(4), 703-10.

O'Connor, O. J., Fitzgerald, E., & Maher, M. M. (2010). Imaging of hematuria. AJR. American journal of roentgenology, 195(4), W263-7.

Oddens, J., Brausi, M., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., Gontero, P., Hoeltl, W., ... Oosterlinck, W. (2013). Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. European urology, 63(3), 462-72.

Oge, O., Erdem, E., Atsu, N., ahin, A., & Ozen, H. (2000). Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. European urology, 37(3), 271-4.

Oing, C., Rink, M., Oechsle, K., Seidel, C., von Amsberg, G., & Bokemeyer, C. (2016). Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. The Journal of urology, 195(2), 254-63.

Oliai, C., Fisher, B., Jani, A., Wong, M., Poli, J., Brady, L. W., & Komarnicky, L. T. (2012). Hyperbaric Oxygen Therapy for Radiation-Induced Cystitis and Proctitis. International journal of radiation oncology, biology, physics, 84(3), 733-740.

Onishi, T., Sasaki, T., Hoshina, A., & Yabana, T. (2011). Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor. Anticancer research, 31(4), 1471-4.

Onishi, T., Sugino, Y., Shibahara, T., Masui, S., Yabana, T., & Sasaki, T. (2017). Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. BJU international, 119(2), 276-282.

Oosterhuis, J. W., Schapers, R. F., Janssen-Heijnen, M. L., Pauwels, R. P., Newling, D. W., & ten Kate, F. (2002). Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. Journal of clinical pathology, 55(12), 900-5.

Oosterlinck, W., Kurth, K. H., Schröder, F., Bultinck, J., Hammond, B., & Sylvester, R. (1993). A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. The Journal of urology, 149(4), 749-52.

Ordell Sundelin, M., & Jensen, J. B. (2017). Asymptomatic microscopic hematuria as a predictor of neoplasia in the urinary tract. Scandinavian journal of urology, 51(5), 373-375.

Palou, J., Baniel, J., Klotz, L., Wood, D., Cookson, M., Lerner, S., Horie, S., Schoenberg, M., ... Bassi, P. (2007). Urothelial carcinoma of the prostate. Urology, 69(1 Suppl), 50-61.

Panebianco, V., Narumi, Y., Altun, E., Bochner, B. H., Efstathiou, J. A., Hafeez, S., Huddart, R., Kennish, S., ... Catto, J. W. F. (2018). Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). European urology, 74(3), 294-306.

Paner, G. P., Lopez-Beltran, A., Sirohi, D., & Amin, M. B. (2016). Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin. Advances in anatomic pathology, 23(2), 71-83.

Park, J. J., Park, B. K., & Kim, C. K. (2016). Single-phase DECT with VNCT compared with three-phase CTU in patients with haematuria. European radiology, 26(10), 3550-7.

Parkin, D. M., Boyd, L., & Walker, L. C. (2011). 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. British journal of cancer, 105(Suppl 2), S77-81.

Pashos, C. L., Botteman, M. F., Laskin, B. L., & Redaelli, A. (2002). Bladder cancer: epidemiology, diagnosis, and management. Cancer practice, 10(6), 311-22.

Peyronnet, B., Seisen, T., Dominguez-Escrig, J. L., Bruins, H. M., Yuan, C. Y., Lam, T., Maclennan, S., N'Dow, J., ... Roupret, M. (2019). Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. European urology focus, 5(2), 205-223.

Pfister, C., Gravis, G., Fléchon, A., Chevreau, C., Mahammedi, H., Laguerre, B., Guillot, A., Joly, F., ... Culine, S. (2022). Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. Journal of Clinical Oncology, 40(18), 2013-2022.

Pfister, C., Gravis, G., Flechon, A., Chevreau, C., Mahammedi, H., Laguerre, B., Guillot, A., Joly, F., ... Culine, S. (2024). Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. The Lancet. Oncology, 25(2), 255-264.

Pfister, C., Gravis, G., Fléchon, A., Soulié, M., Guy, L., Laguerre, B., Mottet, N., Joly, F., ... Culine, S. (2021). Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. European urology, 79(2), 214-221.

Picozzi, S. C., Ricci, C., Gaeta, M., Casellato, S., Bozzini, G., Ratti, D., & Carmignani, L. (2012). Is it oncologically safe performing simultaneous transurethral resection of the bladder and prostate? A meta-analysis on 1,234 patients. International urology and nephrology, 44(5), 1325-33.

Plimack, E. R., Hoffman-Censits, J. H., Viterbo, R., Trabulsi, E. J., Ross, E. A., Greenberg, R. E., Chen, D. Y. T., Lallas, C. D., ... Hudes, G. R. (2014). Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. Journal of Clinical Oncology, 32(18), 1895-901.

Ploussard, G., Daneshmand, S., Efstathiou, J. A., Herr, H. W., James, N. D., Rodel, C. M., Shariat, S. F., Shipley, W. U., ... Kassouf, W. (2014). Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. European urology, 66(1), 120-137.

Pommer, W., Bronder, E., Klimpel, A., Helmert, U., Greiser, E., & Molzahn, M. (1999). Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrology, dialysis, transplantation, 14(12), 2892-7.

Porter, M. P., Gore, J. L., & Wright, J. L. (2011). Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study. World journal of urology, 29(1), 73-7.

Porter, M. P., Kerrigan, M. C., Donato, B. M., & Ramsey, S. D. (2011). Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urologic oncology, 29(3), 252-8.

Portner, R., Bajaj, A., Elumalai, T., Huddart, R., Murthy, V., Nightingale, H., Patel, K., Sargos, P., ... Choudhury, A. (2021). A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer. Clinical and translational radiation oncology, 31, 1-7.

Poulsen, A. L., Horn, T., & Steven, K. (1998). Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. The Journal of urology, 160(6 Pt 1), 2015-9; discussion 2020.

Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., ... Ravaud, A. (2018). Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 391(10122), 748-757.

Powles, T., Kockx, M., Rodriguez-Vida, A., Duran, I., Crabb, S. J., Van Der Heijden, M. S., Szabados, B., Pous, A. F., ... Castellano, D. (2019). Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature medicine, 25(11), 1706-1714.

Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Demey, W., ... Grivas, P. (2020). Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England journal of medicine, 383(13), 1218-1230.

Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J. L., Matsubara, N., Vulsteke, C., ... Petrylak, D. P. (2021). Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. New England journal of medicine, 384(12), 1125-1135.

Powles, T., Valderrama, B. P., Gupta, S., Bedke, J., Kikuchi, E., Hoffman-Censits, J., Iyer, G., Vulsteke, C., ... van der Heijden, M. S. (2024). Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. New England journal of medicine, 390(10), 875-888.

Pradere, B., Lotan, Y., & Roupret, M. (2017). Lynch syndrome in upper tract urothelial carcinoma: significance, screening, and surveillance. Current opinion in urology, 27(1), 48-55.

Pruthi, R. S., Baldwin, N., Bhalani, V., & Wallen, E. M. (2008). Conservative management of low risk superficial bladder tumors. The Journal of urology, 179(1), 87-90; discussion 90.

Raggi, D., Miceli, R., Sonpavde, G., Giannatempo, P., Mariani, L., Galsky, M. D., Bellmunt, J., & Necchi, A. (2016). Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Annals of oncology, 27(1), 49-61.

Rai, B. P., Bondad, J., Vasdev, N., Adshead, J., Lane, T., Ahmed, K., Khan, M. S., Dasgupta, P., ... Aboumarzouk, O. M. (2019). Robotic versus open radical cystectomy for bladder cancer in adults. Cochrane database of systematic reviews, 4(4), CD011903.

Rai, B. P., Luis Dominguez Escrig, J., Vale, L., Kuusk, T., Capoun, O., Soukup, V., Bruins, H. M., Yuan, Y., ... Imran Omar, M. (2022). Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. European urology, 82(2), 182-192.

Raitanen, M. P., Aine, R., Rintala, E., Kallio, J., Rajala, P., Juusela, H., & Tammela, T. L. (2002). Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. European urology, 41(3), 284-9.

Raman, J. D., Messer, J., Sielatycki, J. A., & Hollenbeak, C. S. (2011). Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU international, 107(7), 1059-64.

Raman, J. D., Shariat, S. F., Karakiewicz, P. I., Lotan, Y., Sagalowsky, A. I., Roscigno, M., Montorsi, F., Bolenz, C., ... Margulis, V. (2011). Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. Urologic oncology, 29(6), 716-23.

Rasmussen, P. V., Dalgaard, F., Gislason, G. H., Brandes, A., Johnsen, S. P., Grove, E. L., Torp-Pedersen, C., Münster, A. B., ... Hansen, M. L. (2021). Haematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants. European heart journal. Cardiovascular pharmacotherapy, 7(5), 373-379.

Ray, E. R., Chatterton, K., Khan, M. S., Chandra, A., Thomas, K., Dasgupta, P., & O'Brien, T. S. (2010). Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU international, 105(6), 789-94.

RCC (2015). Cancer i urinblåsa, njurbäcken, urin-ledare och urinrör: nationellt vårdprogram (rev. utg.) Lund: Regionala cancercentrum i Samverkan. Hentet fra http://www.cancercentrum.se/globalassets/cancerdiagnoser/urinvagar/urinblase--och-urinrorscancer/vardprogram/natvp_cancer_urinvagar_25aug15.pdf

Renard-Penna, R., Rocher, L., Roy, C., André, M., Bellin, M. F., Boulay, I., Eiss, D., Girouin, N., ... Rouvière, O. (2020). Imaging protocols for CT urography: results of a consensus conference from the French Society of Genitourinary Imaging. European radiology, 30(3), 1387-1396.

Richterstetter, M., Wullich, B., Amann, K., Haeberle, L., Engehausen, D. G., Goebell, P. J., & Krause, F. S. (2012). The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU international, 110(2 Pt 2), E76-9.

Rink, M., Crivelli, J. J., Shariat, S. F., Chun, F. K., Messing, E. M., & Soloway, M. S. (2015). Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. European urology focus, 1(1), 17-27.

Rink, M., Furberg, H., Zabor, E. C., Xylinas, E., Babjuk, M., Pycha, A., Lotan, Y., Karakiewicz, P. I., ... Shariat, S. F. (2013). Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. European urology, 63(4), 724-32.

Rischmann, P., Desgrandchamps, F., Malavaud, B., & Chopin, D. K. (2000). BCG intravesical instillations: recommendations for side-effects management. European urology, 37 Suppl 1, 33-6.

Rodriguez, J. F., Packiam, V. T., Boysen, W. R., Johnson, S. C., Smith, Z. L., Smith, N. D., Shalhav, A. L., & Steinberg, G. D. (2017). Utilization and Outcomes of Nephroureterectomy for Upper Tract Urothelial Carcinoma by Surgical Approach. Journal of endourology, 31(7), 661-665.

Rojas, C. P., Castle, S. M., Llanos, C. A., Santos Cortes, J. A., Bird, V., Rodriguez, S., Reis, I. M., Zhao, W., ... Jorda, M. (2013). Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. Urologic oncology, 31(8), 1696-700.

Roscigno, M., Brausi, M., Heidenreich, A., Lotan, Y., Margulis, V., Shariat, S. F., Van Poppel, H., & Zigeuner, R. (2011). Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. European urology, 60(4), 776-83.

Roscigno, M., Shariat, S. F., Margulis, V., Karakiewicz, P., Remzi, M., Kikuchi, E., Zigeuner, R., Weizer, A., ... Montorsi, F. (2009). The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed?. European urology, 56(3), 512-8.

Rose, T. L., Harrison, M. R., Deal, A. M., Ramalingam, S., Whang, Y. E., Brower, B., Dunn, M., Osterman, C. K., ... Milowsky, M. I. (2021). Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 39(28), 3140-3148.

Rosenberg, J. E., Carroll, P. R., & Small, E. J. (2005). Update on chemotherapy for advanced bladder cancer. The Journal of urology, 174(1), 14-20.

Rosenberg, J. E., Galsky, M. D., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., ... Bajorin, D. (2024). Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial. ESMO open, 9(12), 103972.

Rosenthal, D. L., Wojcik, E. M., Kurtycz, D. F. I. (2016). The Paris System for Reporting Urinary Cytology. Springer.

Rota, M., Bosetti, C., Boccia, S., Boffetta, P., & La Vecchia, C. (2014). Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers: an updated systematic review and a meta-analysis to 2014. Archives of toxicology, 88(8), 1479-90.

Roth, B., Wissmeyer, M. P., Zehnder, P., Birkhauser, F. D., Thalmann, G. N., Krause, T. M., & Studer, U. E. (2010). A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. European urology, 57(2), 205-11.

Rothman, N., Garcia-Closas, M., Chatterjee, N., Malats, N., Wu, X., Figueroa, J. D., Real, F. X., Van Den Berg, D., ... Chanock, S. J. (2010). A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature genetics, 42(11), 978-84.

Rouprêt, M., Babjuk, M., Compérat, E., Zigeuner, R., Sylvester, R. J., Burger, M., Cowan, N. C., Böhle, A., ... Shariat, S. F. (2015). European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. European urology, 68(5), 868-79.

Rouprët, M., Babjuk, M., Compérat, E., Zigeuner, R., Sylvester, R., Burger, M., Cowan, N., Bohle, A., ... Shariat, S. F. (2013). European guidelines on upper tract urothelial carcinomas: 2013 update. European urology, 63(6), 1059-71.

Sanchez-Ortiz, R. F., Huang, W. C., Mick, R., Van Arsdalen, K. N., Wein, A. J., & Malkowicz, S. B. (2003). An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. The Journal of urology, 169(1), 110-115.

Saylor, P. J., Armstrong, A. J., Fizazi, K., Freedland, S., Saad, F., Smith, M. R., Tombal, B., & Pienta, K. (2013). New and emerging therapies for bone metastases in genitourinary cancers. European urology, 63(2), 309-20.

Schmidbauer, J., Witjes, F., Schmeller, N., Donat, R., Susani, M., Marberger, M., & Hexvix PCB301/01 Study Group (2004). Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. The Journal of urology, 171(1), 135-8.

Scosyrev, E., Ely, B. W., Messing, E. M., Speights, V. O., Grossman, H. B., Wood, D. P., de Vere White, R. W., Vogelzang, N. J., ... Thompson, I. M. (2011). Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU international, 108(5), 693-9.

Seisen, T., Krasnow, R. E., Bellmunt, J., Rouprêt, M., Leow, J. J., Lipsitz, S. R., Vetterlein, M. W., Preston, M. A., ... Chang, S. L. (2017). Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 35(8), 852-860.

Seisen, T., Peyronnet, B., Dominguez-Escrig, J. L., Bruins, H. M., Yuan, C. Y., Babjuk, M., Böhle, A., Burger, M., ... Rouprêt, M. (2016). Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. European urology, 70(6), 1052-1068.

Serretta, V., Altieri, V., Morgia, G., Di Lallo, A., Carrieri, G., & Allegro, R. (2013). Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. Urology, 81(2), 277-81.

Serretta, V., Pavone, C., Ingargiola, G. B., Daricello, G., Allegro, R., & Pavone-Macaluso, M. (2004). TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. European urology, 45(6), 730-5; discussion 735-6.

Shabsigh, A., Korets, R., Vora, K. C., Brooks, C. M., Cronin, A. M., Savage, C., Raj, G., Bochner, B. H., ... Donat, S. M. (2009). Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. European urology, 55(1), 164-74.

Shapur, N. K., Katz, R., Pode, D., Shapiro, A., Yutkin, V., Pizov, G., Appelbaum, L., Zorn, K. C., ... Gofrit, O. N. (2011). Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors, 3(2), e22.

Sharks, J. H., Chandra, A., McWilliam, L., Varma, M. (2013). Standards and datasets for reporting cancers: dataset for tumours of the urinary collecting system (renal pelvis, ureter, urinary bladder and urethra) (2 utg.) London: The Royal College of Pathologists. Hentet fra https://www.rcpath.org/asset/E2C11FF6-780A-471E-A21A4DC48788D35B/

Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., ... Galsky, M. D. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. The Lancet. Oncology, 18(3), 312-322.

Shelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K., & Mason, M. D. (2001). A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU international, 88(3), 209-16.

Shelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., & Mason, M. D. (2004). Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU international, 93(4), 485-490.

Shipley, W. U., Kaufman, D. S., Zehr, E., Heney, N. M., Lane, S. C., Thakral, H. K., Althausen, A. F., & Zietman, A. L. (2002). Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology, 60(1), 62-7; discussion 67-8.

Siefker-Radtke, A. (2012). Urachal adenocarcinoma: a clinician's guide for treatment. Seminars in Oncology, 39(5), 619-24.

Simone, G., Papalia, R., Guaglianone, S., Ferriero, M., Leonardo, C., Forastiere, E., & Gallucci, M. (2009). Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. European urology, 56(3), 520-6.

Skinner, D. G., Daniels, J. R., Russell, C. A., Lieskovsky, G., Boyd, S. D., Nichols, P., Kern, W., Sakamoto, J., ... Groshen, S. (1991). The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. The Journal of urology, 145(3), 459-64; discussion 464-7.

Sobin, D. H., Gospodarwicz, M. K., Wittekind, C. (2010). Urinary Bladder. I: TNM Classification of Malignant Tumours. Wiley-Blackwell.

Soloway, M. S., Bruck, D. S., & Kim, S. S. (2003). Expectant management of small, recurrent, noninvasive papillary bladder tumors. The Journal of urology, 170(2 Pt 1), 438-41.

Solsona, E., Iborra, I., Dumont, R., Rubio-Briones, J., Casanova, J., & Almenar, S. (2000). The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. The Journal of urology, 164(3), 685-689.

Solsona, E., Iborra, I., Ricós, J. V., Monrós, J. L., Casanova, J., & Dumont, R. (1999). Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. The Journal of urology, 161(4), 1120-3.

Sosnowski, R., & Przewozniak, K. (2014). The role of the urologist in smoking cessation: Why is it important?. Urologic oncology, 33(1), 30-39.

Spiess, P. E., Kassouf, W., Brown, G., Highshaw, R., Wang, X., Do, K. A., Kamat, A. M., Czerniak, B., ... Grossman, H. B. (2006). Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?. Urology, 67(3), 466-71.

Stein, J. P., Clark, P., Miranda, G., Cai, J., Groshen, S., & Skinner, D. G. (2005). Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. The Journal of urology, 173(4), 1163-8.

Stenzl, A., Bartsch, G., & Rogatsch, H. (2002). The remnant urothelium after reconstructive bladder surgery. European urology, 41(2), 124-31.

Stenzl, A., Burger, M., Fradet, Y., Mynderse, L. A., Soloway, M. S., Witjes, J. A., Kriegmair, M., Karl, A., ... Grossman, H. B. (2010). Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. The Journal of urology, 184(5), 1907-13.

Stenzl, A., Cowan, N. C., De Santis, M., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., Sherif, A., Witjes, J. A., & European Association of, U. (2011). Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. European urology, 59(6), 1009-18.

Stenzl, A., Nagele, U., Kuczyk, M., Sievert, K., Anastasiadis, A., Seibold, J., & Corvin, S. (2005). Cystectomy - Technical Considerations in Male and Female Patients. EAU Update Series, 3(3), 138-146.

Sternberg, C. N., Bellmunt, J., Sonpavde, G., Siefker-Radtke, A. O., Stadler, W. M., Bajorin, D. F., Dreicer, R., George, D. J., ... International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder, C. (2013). ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. European urology, 63(1), 58-66.

Sternberg, C. N., Pansadoro, V., Calabro, F., Schnetzer, S., Giannarelli, D., Emiliozzi, P., De, P. F., Scarpone, P., ... Amini, M. (2003). Can patient selection for bladder preservation be based on response to chemotherapy?. Cancer, 97(7), 1644-1652.

Sternberg, C. N., Skoneczna, I., Kerst, J. M., Albers, P., Fossa, S. D., Agerbaek, M., Dumez, H., de Santis, M., ... Sylvester, R. (2015). Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. The Lancet. Oncology, 16(1), 76-86.

Sternberg, C. N., & Vogelzang, N. J. (2003). Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Critical reviews in oncology/hematology, 46 Suppl(Suppl), S105-15.

Stockle, M., Meyenburg, W., Wellek, S., Voges, G. E., Rossmann, M., Gertenbach, U., Thuroff, J. W., Huber, C., & Hohenfellner, R. (1995). Adjuvant Polychemotherapy of Nonorgan-Confined Bladder-Cancer after Radical Cystectomy Revisited - Long-Term Results of a Controlled Prospective-Study and Further Clinical-Experience. The Journal of urology, 153(1), 47-52.

Studer, U. E., & Collette, L. (2006). Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy. European urology, 50(5), 887-9; discussion 889-92.

Sugihara, T., Yasunaga, H., Horiguchi, H., Matsui, H., Nishimatsu, H., Nakagawa, T., Fushimi, K., Kattan, M. W., & Homma, Y. (2014). Comparison of perioperative outcomes including severe bladder injury between monopolar and bipolar transurethral resection of bladder tumors: a population based comparison. The Journal of urology, 192(5), 1355-9.

Svatek, R. S., Shariat, S. F., Lasky, R. E., Skinner, E. C., Novara, G., Lerner, S. P., Fradet, Y., Bastian, P. J., ... Dinney, C. P. (2010). The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clinical cancer research : an official journal of the American Association for Cancer Research, 16(17), 4461-7.

Sweeney, M. K., Rais-Bahrami, S., & Gordetsky, J. (2017). Inverted urothelial papilloma: A review of diagnostic pitfalls and clinical management. Canadian Urological Association journal, 11(1-2), 66-69.

Sweeney, P., Millikan, R., Donat, M., Wood, C. G., Radtke, A. S., Pettaway, C. A., Grossman, H. B., Dinney, C. P., ... Pisters, L. L. (2003). Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?. The Journal of urology, 169(6), 2113-7.

Sylvester, R. J., Oosterlinck, W., Holmang, S., Sydes, M. R., Birtle, A., Gudjonsson, S., De Nunzio, C., Okamura, K., ... Babjuk, M. (2016). Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?. European urology, 69(2), 231-44.

Sylvester, R. J., van der, M. A., & Lamm, D. L. (2002). Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. The Journal of urology, 168(5), 1964-70.

Sylvester, R. J., van der Meijden, A., Witjes, J. A., Jakse, G., Nonomura, N., Cheng, C., Torres, A., Watson, R., & Kurth, K. H. (2005). High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology, 66(6 Suppl 1), 90-107.

Sylvester, R. J., van der Meijden, A. P., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D. W., & Kurth, K. (2006). Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European urology, 49(3), 466-5; discussion 475-7.

Szarvas, T., Módos, O., Niedworok, C., Reis, H., Szendröi, A., Szász, M. A., & Nyirády, P. (2016). Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases. Urologic oncology, 34(9), 388-98.

Søndergaard, J., Holmberg, M., Jakobsen, A. R., Agerbæk, M., Muren, L. P., & Høyer, M. (2014). A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. Acta oncologica (Stockholm, Sweden), 53(10), 1321-8.

Takenaka, A., Yamada, Y., Miyake, H., Hara, I., & Fujisawa, M. (2008). Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder. International journal of urology, 15(4), 309-13.

Takeuchi, M., Konrad, A. J., Kawashima, A., Boorjian, S. A., & Takahashi, N. (2015). CT Urography for Diagnosis of Upper Urinary Tract Urothelial Carcinoma: Are Both Nephrographic and Excretory Phases Necessary?. AJR. American journal of roentgenology, 205(3), W320-7.

Tan, W. S., Feber, A., Sarpong, R., Khetrapal, P., Rodney, S., Jalil, R., Mostafid, H., Cresswell, J., ... Kelly, J. D. (2018). Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. European urology, 74(1), 10-14.

Tanrikut, C., & McDougal, W. S. (2004). Acid-base and electrolyte disorders after urinary diversion. World journal of urology, 22(3), 168-71.

Teoh, J. Y., Chan, E. S., Yip, S. Y., Tam, H. M., Chiu, P. K., Yee, C. H., Wong, H. M., Chan, C. K., ... Ng, C. F. (2017). Comparison of Detrusor Muscle Sampling Rate in Monopolar and Bipolar Transurethral Resection of Bladder Tumor: A Randomized Trial. Annals of surgical oncology, 24(5), 1428-1434.

Teoh, J. Y., Mayor, N., Li, K. M., Lo, K. L., Ng, C. F., & Mostafid, H. (2021). En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting. World journal of urology, 39(9), 3353-3358.

Thoeny, H. C., Sonnenschein, M. J., Madersbacher, S., Vock, P., & Studer, U. E. (2002). Is ileal orthotopic bladder substitution with an afferent tubular segment detrimental to the upper urinary tract in the long term?. The Journal of urology, 168(5), 2030-2034.

Tinazzi, E., Ficarra, V., Simeoni, S., Artibani, W., & Lunardi, C. (2006). Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatology international, 26(6), 481-8.

Torbrand, C., Håkansson, U., Ehrnström, R., & Liedberg, F. (2017). Diagnosing Distal Urethral Carcinomas in Men Might Be Only the Tip of the Iceberg. Clinical genitourinary cancer, 15(6), e1131-e1135.

Touijer, A. K., & Dalbagni, G. (2004). Role of voided urine cytology in diagnosing primary urethral carcinoma. Urology, 63(1), 33-5.

Tsivian, A., Shtricker, A., & Sidi, A. A. (2003). Simultaneous transurethral resection of bladder tumor and benign prostatic hyperplasia: hazardous or a safe timesaver?. The Journal of urology, 170(6 Pt 1), 2241-3.

Tubiana, M. (2009). Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiotherapy and oncology, 91(1), 4-15; discussion 1-3.

Tunio, M. A., Hashmi, A., Qayyum, A., Mohsin, R., & Zaeem, A. (2012). Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. International journal of radiation oncology, biology, physics, 82(3), e457-62.

van der Heijden, M. S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., Schenker, M., Sade, J. P., Bamias, A., ... Galsky, M. D. (2023). Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. New England journal of medicine, 389(19), 1778-1789.

Van Der Meijden, A., Sylvester, R., Collette, L., Bono, A., & Ten Kate, F. (2000). The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. The Journal of urology, 164(5), 1533-7.

van der Meijden, A. P., Sylvester, R. J., Oosterlinck, W., Hoeltl, W., & Bono, A. V. (2003). Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. European urology, 44(4), 429-434.

van der Molen, A. J., Reimer, P., Dekkers, I. A., Bongartz, G., Bellin, M. F., Bertolotto, M., Clement, O., Heinz-Peer, G., ... Thomsen, H. S. (2018). Post-contrast acute kidney injury - Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. European radiology, 28(7), 2845-2855.

van der Molen, A. J., Reimer, P., Dekkers, I. A., Bongartz, G., Bellin, M. F., Bertolotto, M., Clement, O., Heinz-Peer, G., ... Thomsen, H. S. (2018). Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. European radiology, 28(7), 2856-2869.

van der Post, R. S., Kiemeney, L. A., Ligtenberg, M. J., Witjes, J. A., Hulsbergen-van de Kaa, C. A., Bodmer, D., Schaap, L., Kets, C. M., ... Hoogerbrugge, N. (2010). Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. Journal of medical genetics, 47(7), 464-70.

van Doeveren, T., van der Mark, M., van Leeuwen, P. J., Boormans, J. L., & Aben, K. K. H. (2021). Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017. BJU international, 128(3), 343-351.

van Helvoirt, R. (2021). Palliativ strålebehandling av blærekreft. Onkonytt, (1), 24-28.

van Rhijn, B. W., van der Kwast, T. H., Vis, A. N., Kirkels, W. J., Boevé, E. R., Jöbsis, A. C., & Zwarthoff, E. C. (2004). FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer research, 64(6), 1911-4.

van Rhijn, B. W., van der Poel, H. G., & van der Kwast, T. H. (2005). Urine markers for bladder cancer surveillance: a systematic review. European urology, 47(6), 736-48.

Vasen, H. F., Möslein, G., Alonso, A., Bernstein, I., Bertario, L., Blanco, I., Burn, J., Capella, G., ... Wijnen, J. (2007). Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). Journal of medical genetics, 44(6), 353-62.

Venkatramani, V., Panda, A., Manojkumar, R., & Kekre, N. S. (2014). Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. The Journal of urology, 191(6), 1703-7.

Veskimae, E., Neuzillet, Y., Rouanne, M., MacLennan, S., Lam, T. B. L., Yuan, Y., Comperat, E., Cowan, N. C., ... Lebret, T. (2017). Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU international, 120(1), 12-24.

Vetterlein, M. W., Seisen, T., May, M., Nuhn, P., Gierth, M., Mayr, R., Fritsche, H. M., Burger, M., ... Aziz, A. (2018). Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. European urology focus, 4(2), 252-259.

Vetterlein, M. W., Wankowicz, S. A. M., Seisen, T., Lander, R., Löppenberg, B., Chun, F. K., Menon, M., Sun, M., ... Preston, M. A. (2017). Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer, 123(22), 4346-4355.

Vogelzang, N. J. (2013). Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma. Journal of Clinical Oncology, 31(6), 670-5.

von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., ... Conte, P. F. (2000). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology, 18(17), 3068-3077.

von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of Clinical Oncology, 23(21), 4602-8.

Wallis, C. J., Mahar, A. L., Choo, R., Herschorn, S., Kodama, R. T., Shah, P. S., Danjoux, C., Narod, S. A., & Nam, R. K. (2016). Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. British medical journal, 352, i851.

Wallis, C. J. D., Juvet, T., Lee, Y., Matta, R., Herschorn, S., Kodama, R., Kulkarni, G. S., Satkunasivam, R., ... Nam, R. K. (2017). Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. Jama, 318(13), 1260-1271.

Wang, J. K., Tollefson, M. K., Krambeck, A. E., Trost, L. W., & Thompson, R. H. (2012). High rate of pathologic upgrading at nephroureterectomy for upper tract urothelial carcinoma. Urology, 79(3), 615-9.

Wasco, M. J., Daignault, S., Zhang, Y., Kunju, L. P., Kinnaman, M., Braun, T., Lee, C. T., & Shah, R. B. (2007). Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology, 70(1), 69-74.

Weiss, C., Engehausen, D. G., Krause, F. S., Papadopoulos, T., Dunst, J., Sauer, R., & Rodel, C. (2007). Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. International journal of radiation oncology, biology, physics, 68(4), 1072-80.

Wennersten, C., Andersson, G., Boman, K., Nodin, B., Gaber, A., & Jirstrom, K. (2014). Incident urothelial cancer in the Malmo Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker. Diagnostic pathology, 9(1), 189.

WHO Classification of Tumours Editorial Board (2022). WHO Classification of Tumours: Urinary and Male Genital Tumours. IARC.

Widmark, A., Flodgren, P., Damber, J. E., Hellsten, S., & Cavallin-Stahl, E. (2003). A systematic overview of radiation therapy effects in urinary bladder cancer. Acta oncologica (Stockholm, Sweden), 42(5-6), 567-581.

Wiesner, C., Bonfig, R., Stein, R., Gerharz, E. W., Pahernik, S., Riedmiller, H., & Thuroff, J. W. (2006). Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs. World journal of urology, 24(3), 315-318.

Wiesner, C., Stein, R., Pahernik, S., Hahn, K., Melchior, S. W., & Thuroff, J. W. (2006). Long-term followup of the intussuscepted ileal nipple and the in situ, submucosally embedded appendix as continence mechanisms of continent urinary diversion with the cutaneous ileocecal pouch (Mainz pouch I). The Journal of urology, 176(1), 155-159.

Wijkstrom, H., Norming, U., Lagerkvist, M., Nilsson, B., Naslund, I., & Wiklund, P. (1998). Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. British journal of urology, 81(5), 686-691.

Willis, D., & Kamat, A. M. (2015). Nonurothelial bladder cancer and rare variant histologies. Hematology/oncology clinics of North America, 29(2), 237-52, viii.

Willis, D. L., Fernandez, M. I., Dickstein, R. J., Parikh, S., Shah, J. B., Pisters, L. L., Guo, C. C., Henderson, S., ... Kamat, A. M. (2015). Clinical outcomes of cT1 micropapillary bladder cancer. The Journal of urology, 193(4), 1129-34.

Wilson, T. G., Guru, K., Rosen, R. C., Wiklund, P., Annerstedt, M., Bochner, B. H., Chan, K. G., Montorsi, F., ... Catto, J. (2015). Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. European urology, 67(3), 363-75.

Witjes, J. A., Babjuk, M., Bellmunt, J., Bruins, H. M., De Reijke, T. M., De Santis, M., Gillessen, S., James, N., ... Horwich, A. (2020). EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(†): Under the Auspices of the EAU-ESMO Guidelines Committees. European urology, 77(2), 223-250.

Woo, S., Suh, C. H., Kim, S. Y., Cho, J. Y., & Kim, S. H. (2018). The Diagnostic Performance of MRI for Detection of Lymph Node Metastasis in Bladder and Prostate Cancer: An Updated Systematic Review and Diagnostic Meta-Analysis. AJR. American journal of roentgenology, 210(3), W95-w109.

Wood, D. N., Allen, S. E., Hussain, M., Greenwell, T. J., & Shah, P. J. R. (2004). Stomal complications of ileal conduits are significantly higher when formed in women with intractable urinary incontinence. The Journal of urology, 172(6), 2300-2303.

Woodford, R., Ranasinghe, W., Aw, H. C., Sengupta, S., & Persad, R. (2016). Trends in incidence and survival for upper tract urothelial cancer (UTUC) in the state of Victoria--Australia. BJU international, 117 Suppl 4, 45-9.

Xiong, G., Yao, L., Hong, P., Yang, L., Ci, W., Liu, L., He, Q., Gong, K., ... Zhou, L. (2018). Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients. Cancer management and research, 10, 6627-6639.

Yafi, F. A., Brimo, F., Steinberg, J., Aprikian, A. G., Tanguay, S., & Kassouf, W. (2015). Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urologic oncology, 33(2), 66.e25-31.

Yafi, F. A., Tanguay, S., Rendon, R., Jacobsen, N., Fairey, A., Izawa, J., Kapoor, A., Black, P., ... Kassouf, W. (2014). Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urologic oncology, 32(1), 31.e17-24.

Yamany, T., van Batavia, J., Ahn, J., Shapiro, E., & Gupta, M. (2015). Ureterorenoscopy for upper tract urothelial carcinoma: how often are we missing lesions?. Urology, 85(2), 311-5.

Yanagisawa, T., Mori, K., Motlagh, R. S., Kawada, T., Mostafaei, H., Quhal, F., Laukhtina, E., Rajwa, P., ... Shariat, S. F. (2022). En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. The Journal of urology, 207(4), 754-768.

Ye, L., Chen, Y., Xu, H., Xie, H., Yao, J., Liu, J., & Song, B. (2022). Biparametric magnetic resonance imaging assessment for detection of muscle-invasive bladder cancer: a systematic review and meta-analysis. European radiology, 32(9), 6480-6492.

Ye, Z., Hu, J., Song, X., Li, F., Zhao, X., Chen, S., Wang, X., He, D., ... Wang, D. (2015). A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. Scientific reports, 5, 10905.

Yin, M., Joshi, M., Meijer, R. P., Glantz, M., Holder, S., Harvey, H. A., Kaag, M., Fransen van de Putte, E. E., ... Drabick, J. J. (2016). Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. The oncologist, 21(6), 708-15.

Yu, Y. D., Ko, Y. H., Kim, J. W., Jung, S. I., Kang, S. H., Park, J., Seo, H. K., Kim, H. J., ... Oh, J. J. (2021). The Prognosis and Oncological Predictor of Urachal Carcinoma of the Bladder: A Large Scale Multicenter Cohort Study Analyzed 203 Patients With Long Term Follow-Up. Frontiers in oncology, 11, 683190.

Zaghloul, M. S., Boutrus, R., El-Hossieny, H., Kader, Y. A., El-Attar, I., & Nazmy, M. (2010). A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. International journal of clinical oncology, 15(4), 382-9.

Zehnder, P., Studer, U. E., Skinner, E. C., Dorin, R. P., Cai, J., Roth, B., Miranda, G., Birkhauser, F., ... Skinner, D. G. (2011). Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. The Journal of urology, 186(4), 1261-8.

Zhao, H., Chan, V. W., Castellani, D., Chan, E. O., Ong, W. L. K., Peng, Q., Moschini, M., Krajewski, W., ... Teoh, J. Y. (2021). Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Frontiers in surgery, 8, 775527.

Zheng, C., Lv, Y., Zhong, Q., Wang, R., & Jiang, Q. (2012). Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU international, 110(11 Pt B), E680-7.

Zhou, Z., Zhao, S., Lu, Y., Wu, J., Li, Y., Gao, Z., Yang, D., & Cui, Y. (2019). Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors. World journal of urology, 37(6), 1075-1084.

Zieger, K., Wolf, H., Olsen, P. R., & Hojgaard, K. (2000). Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression. BJU international, 85(7), 824-8.

Zietman, A. L., Sacco, D., Skowronski, U., Gomery, P., Kaufman, D. S., Clark, J. A., Talcott, J. A., & Shipley, W. U. (2003). Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. The Journal of urology, 170(5), 1772-6.